Novo Nordisk’s Wegovy pill arrives in the US for US$149, intensifying the market dispute

Novo Nordisk, the Danish pharmaceutical giant, has made its long-awaited pill Wegovy available for weight loss in the Estados Unidos. The drug, which imitates the hormone GLP-1 to reduce appetite, hits the market with an initial cost significantly lower than injectable versions. Essa introduction aims to expand access to treatment and intensify competition in the growing obesity medicine sector, which has attracted global attention.
Approval by the US regulatory agency occurred before the last Natal, paving the way for the commercialization of a needle-free alternative. The new Wegovy modality represents an important advancement for patients seeking more convenient and accessible treatments. The company hopes the pill will reach the more than 100 million Americans who live with obesity.
Patients who pay for the treatment in full can purchase the initial dose of 1.5mg for US$149 per month, or US$5 per day. The higher doses will have different prices, with the 4mg version costing US$149 until April 15, and then US$199, while the maximum doses reach US$299 per month.
Impact on the obesity drug market
The arrival of the oral version of Wegovy is seen as a strategic move by Novo Nordisk to reconfigure the panorama of treatments against obesity. By offering a more competitive initial price, the company seeks to attract a larger audience and reaffirm its position in the sector.
This launch occurs amid a fierce dispute with Eli Lilly, the main rival in the segment. Ambas pharmaceutical companies have adjusted the prices of their injections for patients without insurance coverage, reflecting the growing pressure for accessibility.
Pill details and mechanism of action
The Wegovy pill, with its daily formulation, represents a notable advance as it is the first and only oral drug on the market to mimic the hormone GLP-1, essential in appetite regulation. Seu mechanism of action helps promote feelings of satiety and reduce caloric intake, resulting in significant weight loss. Regulatory approval in the Estados Unidos was based on studies that demonstrated an average weight loss of about 17% among patients who remained on treatment, offering an effective, needle-free alternative for those seeking to manage their obesity.
Pricing strategy for patients
Novo Nordisk’s pricing policy for pill Wegovy was designed to attract different patient profiles. Aqueles who pay out of pocket find more affordable options for the initial doses of treatment.
The 1.5mg dose is available for US$149 per month, a value considered below market analysts’ expectations. Essa strategic pricing aims to encourage the initiation of treatment and patient adherence.
For the 4mg dose, the cost will be US$149 per month initially, valid until April 15th, rising to US$199 after that date. The highest dosages of the drug are set at US$299 per month.
Patients with health insurance can benefit from even lower costs, with payments starting at $25 per month. Essa differentiation seeks to maximize product penetration in the diverse North American healthcare market.
Availability and access channels
Initially, the Wegovy pill is available in more than 70 thousand pharmacies in the Estados Unidos, including large chains such as CVS and Costco. Além In addition, Novo Nordisk has expanded access through telemedicine providers such as Ro, LifeMD and Weight Watchers, making it easier for patients to start and maintain treatment with greater convenience. Availability on digital and physical platforms underlines the company’s strategy to reach a vast number of individuals.
Higher doses of the drug will be introduced to the market throughout this week, ensuring that patients can progress with their treatment in accordance with medical guidance. Essa Gradual distribution allows the supply chain to adjust to demand and ensures that the transition between dosages is made in an organized and efficient manner, meeting the needs of users at different stages of treatment.
Market reactions and competition
The launch of the Wegovy pill boosted Novo Nordisk shares, which rose by more than 4% shortly after the announcement. However, the company’s market value fell 44% in the last year, a reflection of intense competition.
Eli Lilly, with its injectables Mounjaro and Zepbound, remains a strong competitor. Ambas companies are engaged in a price war, seeking to attract patients with and without insurance coverage.
Analysts such as Matt Weston, from UBS, pointed out that the price of the Novo Nordisk pill was lower than expected. Anteriormente, weight loss injections in the US cost around $1,000 a month or more, with Novo Nordisk having already reduced the price of its Wegovy injection to $349 monthly for cash payments.
Future scenario and global expectations
While Eli Lilly develops its own anti-obesity pill,







